NHS to provide Pfizer’s Voxelotor to treat sickle cell disease
FDA Confirms Paragraph IV Patent Litigation for Voxelotor Tablets for Oral Suspension
FDA Confirms Paragraph IV Patent Litigation for Voxelotor Tablets
Global Blood Therapeutics` Oxbryta (voxelotor) Receives Approval in Europe
Pfizer`s Oxbryta (Voxelotor) Approved In Europe
Working to grow the reach of its sickle cell disease medicine Adakveo, Novartis has more than just Pfizer's Oxbryta to worry about.
Global Blood Therapeutics (GBT) has announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted Britain marketing authorisation for Oxbryta – also known as voxelotor.
SOUTH SAN FRANCISCO, Calif., July 26, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that the Medicines and Healthcare products Regulatory Agency (MHRA)...
SOUTH SAN FRANCISCO, Calif., July 14, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced the initiation of an expanded access program (EAP) for voxelotor in...
Achieved Oxbryta® (voxelotor) net revenues of $55.2 million in the first quarter 2022, a 41% increase year over year Strong new prescription growth driven by the recent launch for children ages 4...